$51.470
-0.257 (-0.50%)收盘时
AXGN 资讯
AXGN 事件
Company Expects 24% Revenue Growth for 2026
The company said, "For 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and positive free cash flow for the full-year."
Trace Biosciences Receives Strategic Investment from Axogen
Trace Biosciences announced it has received a strategic investment from Axogen as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join.
Axogen Reports Q2 Revenue of $69.73M, Beating Consensus
Reports Q2 revenue $69.73M, consensus $67.1M. "We are pleased with our second-quarter revenue performance and the progress we're making across each of Axogen's strategic plan priorities," said Michael Dale, President and CEO of Axogen, Inc. "Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026."
Neuronetics Appoints Nir Naor as CFO
Neuronetics (STIM) announced that Nir Naor will be appointed CFO effective July 23. Most recently, he served as CFO of Axogen (AXGN). Separately, Andrew Macan, executive VP, chief legal officer and corporate secretary, will step down effective August 15.
AxoGen Stock Rises 12.8% to $44.42
AxoGen is up 12.8%, or $5.03 to $44.42.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。